Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tamibarotene |
| Synonyms | |
| Therapy Description |
Tamibarotene (SY-1425) is a synthetic retinoid that activates retinoic acid receptor signaling, which in turn induces differentiation and apoptosis in leukemia cells (PMID: 17925887, PMID: 30093681). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tamibarotene | Am 80|SY-1425|TOS-80T|INNO-507 | Tamibarotene (SY-1425) is a synthetic retinoid that activates retinoic acid receptor signaling, which in turn induces differentiation and apoptosis in leukemia cells (PMID: 17925887, PMID: 30093681). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02807558 | Phase II | Azacitidine + Tamibarotene Tamibarotene | A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | FRA | 0 |